DiaMedica Therapeutics Inc. (DMAC) Stock Profile — Insider Trades & Financials

Net Income-$8.7M

Market Cap$333.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Dietrich Pauls

CEO & Executive Director

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded: 2000
Employees: 28

⚡

Core Efficiency

ROE?

-15.58%

ROA?

-14.24%

📊

Profitability Ratios

Current Ratio?

11.81

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 16, 2026 (in 160 days)

Annual Report (10-K) — Based on filing pattern

Sep 16, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 20253d after period end

Mar 30, 2026

10-KFY 202589d after period end

Nov 12, 2025

10-QQ3 20252d after period end

Aug 12, 2025

10-QQ2 20254d after period end

May 13, 2025

10-QQ1 20254d after period end

Mar 17, 2025

10-KQ4 20243d after period end

Mar 17, 2025

10-KFY 202576d after period end

Nov 13, 2024

10-QQ3 20242d after period end

Loading company sections...

DiaMedica Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness